A comprehensive understanding of the biologic mechanisms underlying HER2-positive breast cancer is essential to improve treatment strategies, and understanding its relationship with immunity will be a key factor for improving patient outcomes. This evidence concerns the gene ERBB2 and breast carcinoma.